Friday 13 May 2022

Israeli clinical-stage company NeoTX has acquired US-based drug discovery firm InterX, the company said.

InterX, is a drug discovery company utilizing advanced proprietary tools of biomolecular computation for the discovery and design of novel therapeutic molecules based on Nobel Prize Laureate Prof Michael Levitt's discoveries.

These tools allow a detailed quantum mechanical process assessment of biochemical interactions resulting in faster, more accurate and efficient drug discovery.

In addition to the discovery engine, this acquisition also comes with a pipeline of early drugs.

NeoTX is a clinical-stage company developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen platform.

TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response.

The company's lead TTS molecule, naptumomab estafenatox is currently in clinical development for advanced solid tumors.

InterX is a drug development company, based in the United States and Israel, which is revolutionizing biomolecular computation of chemical and biological systems.

The company aims to achieve robust and accurate prediction of molecular and ensemble properties of biological systems using computational methods.

InterX is led by Nobel Prize-winning scientist Roger Kornberg.